Tvardi Therapeutics (NASDAQ:TVRD) Shares Cross Above 50-Day Moving Average – Here’s What Happened

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $1.28 and traded as high as $1.61. Tvardi Therapeutics shares last traded at $1.41, with a volume of 1,863,006 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have commented on TVRD shares. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. BTIG Research lowered their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Chardan Capital initiated coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Tvardi Therapeutics Price Performance

The business has a fifty day moving average of $1.26 and a 200-day moving average of $2.63. The stock has a market capitalization of $17.87 million, a price-to-earnings ratio of -0.48 and a beta of 0.37.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts anticipate that Tvardi Therapeutics, Inc. will post -2.23 EPS for the current year.

Institutional Trading of Tvardi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. BlackRock Inc. bought a new stake in Tvardi Therapeutics during the second quarter worth approximately $181,000. Susquehanna International Group LLP bought a new position in shares of Tvardi Therapeutics in the second quarter valued at $63,000. Finally, GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the second quarter valued at $34,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.